Skip to main content
Accessibility  |  Contact  |  Privacy  |  Terms of Service

Advances in Drugs for Childhood Cancer

  • Published: 2010-03-29 : Author: St. Jude Childrens Research Hospital
  • Synopsis: New class of compounds targeting a protein implicated in promoting a variety of cancers.

Main Document

Advances Reported in Quest for Drugs Targeting Childhood Cancer - St. Jude Children's Research Hospital investigators identify a new class of compounds targeting a protein implicated in promoting a variety of cancers, including a childhood eye tumor.

Investigators believe they have identified the founding member of a chemical family they hope will lead to a new class of cancer drugs, the first designed specifically against a childhood tumor, according to research led by St. Jude Children's Research Hospital scientists.

The chemical is the first small-molecule inhibitor to target the MDMX protein. Excess MDMX is a hallmark of the childhood eye tumor retinoblastoma as well as certain cases of breast, lung, prostate and other cancers. Nationally about 300 new cases of retinoblastoma are identified each year.

The discovery was reported online in advance of the April 2 print edition of the Journal of Biological Chemistry. An overabundance of MDMX or its sister protein, MDM2, can promote tumor progression by binding and suppressing a protein called p53. The role of p53 in normal cells is to induce death in cells that begin the unchecked cell division that is a hallmark of cancer.

MDM2 and MDMX use different mechanisms to disrupt the p53 pathway. There is an emerging scientific consensus that restoring normal p53 function might require shutting down both MDMX and MDM2. A small-molecule inhibitor against MDM2 is already in Phase 1 pharmaceutical industry trials. In this study, St. Jude researchers reported that when the new St. Jude compound, known as SJ-172550, is combined with an MDM2 inhibitor there was a corresponding increase in retinoblastoma cells death.

Michael Dyer, Ph.D., Developmental Neurobiology and the paper's senior author, said several years of detailed chemical studies and additional work are likely needed before SJ-172550 might be ready for human trials.

Evidence suggests SJ-172550 works by binding in a reversible manner to a pocket in the MDMX molecule. With SJ-172550 sitting in the pocket, the p53 protein cannot bind to MDMX, Dyer explained. That makes p53 available to do its job and eliminate tumor cells. About 65 percent of retinoblastoma tumors feature extra copies of the MDMX gene as do nearly 20 percent of patients with breast, colon and lung cancer.

The finding expands on work from Dyer's laboratory into the genetic and biochemical missteps that give rise to retinoblastoma. The advance reflects the combined efforts of the St. Jude departments of Developmental Neurobiology; Chemical Biology and Therapeutics; and Structural Biology. The first authors are Damon Reed, M.D., formerly of St. Jude and now of St. Petersburg, Fla., and Ying Shen, Ph.D., of Developmental Neurobiology.

"We went from a discovery in childhood cancer, MDMX amplification, to characterizing this first inhibitor in about three-and one-half years," Dyer said. "This model is now being replicated over and over in other cancers we treat at St. Jude."

Dyer's laboratory developed the biochemical and cell-based tests used by colleagues in Chemical Biology and Therapeutics. Researchers checked a chemical library of nearly 300,000 compounds using high-throughput screening. Investigators searched for molecules likely to block MDMX activity.

Dyer said the new compound might help researchers studying the biology of MDMX. "It may also be useful for any tumor that has normal p53," he said. "The idea is that if you have normal p53 and you need to turn it on, maybe by giving a drug that hits MDM2 and another that hits MDMX; you free p53 up to kill the cell."

Investigators' predictions of exactly how SJ-172550 interacts with MDMX are based on mathematical and computer models. Work is underway to capture an X-ray crystal structure of SJ-172550 bound to MDMX.

Other St. Jude authors are Anang Shelat, Fangyi Zhu, David Smithson, Kip Guy, Samantha Cicero, Antonio Ferreira, Don Bashford, and Brenda Schulman (St. Jude); Leggy A. Arnold, Catherine A. Regni, and Nicholas Mills (formerly of St. Jude); and Aart Jochemsen (Leiden University Medical Center, Leiden, Netherlands).

The research was supported by grants from the National Institutes of Health, the National Cancer Institute, the American Cancer Society, Research to Prevent Blindness, the Pearle Vision Foundation, the International Retinal Research Foundation, the Pew Charitable Trust, Howard Hughes Medical Institute and ALSAC.

St. Jude Children's Research Hospital

St. Jude Children's Research Hospital is internationally recognized for its pioneering research and treatment of children with cancer and other catastrophic diseases. Ranked the No. 1 pediatric cancer hospital by Parents magazine, St. Jude is the first and only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children, and has treated children from all 50 states and from around the world. St. Jude has developed research protocols that helped push overall survival rates for childhood cancer from less than 20 percent when the hospital opened to almost 80 percent today. St. Jude is the national coordinating center for the Pediatric Brain Tumor Consortium and the Childhood Cancer Survivor Study. In addition to pediatric cancer research, St. Jude is also a leader in sickle cell disease research and is a globally prominent research center for influenza.

Founded in 1962 by the late entertainer Danny Thomas, St. Jude freely shares its discoveries with scientific and medical communities around the world, publishing more research articles than any other pediatric cancer research center in the United States. St. Jude treats more than 5,400 patients each year and is the only pediatric cancer research center where families never pay for treatment not covered by insurance. St. Jude is financially supported by thousands of individual donors, organizations and corporations without which the hospital's work would not be possible. In 2010, St. Jude was ranked the most trusted charity in the nation in a public survey conducted by Harris Interactive, a highly respected international polling and research firm. For more information, go to

Similar Topics

1 : Siblings of Cot Death Victims Have Four Times SIDS Risk : European Society of Cardiology.
2 : Increased Risk for Abuse for Children with Specific Birth Defects : University of Texas Health Science Center at Houston.
3 : Childhood Trauma: Symptoms & Behavior Information : Disabled World.
4 : CHOPS Syndrome: New Early Development Genetic Syndrome : The Children's Hospital of Philadelphia.
5 : Baby Formula - Higher Arsenic Risk than Breast Milk : Dartmouth College.
From our Pediatrics section - Full List (93 Items)

Submit disability news, coming events, as well as assistive technology product news and reviews.

Loan Information for low income singles, families, seniors and disabled. Includes home, vehicle and personal loans.

Famous People with Disabilities - Well known people with disabilities and conditions who contributed to society.

List of awareness ribbon colors and their meaning. Also see our calendar of awareness dates.

Blood Pressure Chart - What should your blood pressure be, and information on blood group types/compatibility.

1 : How Often Do Medical Problems Lead to Bankruptcy?
2 : Videocamp Launches $400,000 Fund and Challenges Filmmakers to Create a Film About Inclusive Education
3 : vEAR: Why Can I Sometimes 'Hear' Silent Flashes When Viewing Animated Gif's?
4 : New Jersey Digital Art Program for Individuals with ASD
5 : 2018 Lime Connect Fellowship Program for Students with Disabilities


Disclaimer: This site does not employ and is not overseen by medical professionals. Content on Disabled World is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. See our Terms of Service for more information.

Reporting Errors: Disabled World is an independent website, your assistance in reporting outdated or inaccurate information is appreciated. If you find an error please let us know.